 WALTHAM, Mass., Nov. 11, 2021 GLOBE NEWSWIRE -- TScan Therapeutics, Inc. Nasdaq: TCRX, a biopharmaceutical company focused on the development of T-cell receptor TCR engineered T cell therapies TCR-T for the treatment of patients with cancer, today announced that the Company will participate virtually at the following upcoming investor conferences: 